ArticleScientific reports2026
Expression and function of CYP enzymes and hepatobiliary transporters in an improved long-term sandwich culture hepatocyte model.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hepatocyte Models for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comparative Analysis of Non-HepG2 Cell Models.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in methodology help long-term in vitro maintenance of primary human hepatocytes (PHH), improving their predictability for drug-induced liver injury. Small-molecule additives, such as 5C, have been described to prolong hepatocyte functionality, however, comprehensive description of CYP enzyme and transporter functions are scarce. Here we show a new hepatic model developed by treating hepatocytes in sandwich configuration with 5C (SPHH-5C), where, besides keeping hepatocytes in a fully differentiated form, their polarization is also supported to achieve more in vivo-like structure. The model is characterized by CYP enzyme and hepatobiliary transporter expression and activity as a function of culture time. Hepatic functions were compared in untreated (SPHH) and 5C-treated sandwich (SPHH-5C) or monolayer cultures (PHH-5C). CYP enzyme and transporter functions were best retained in SPHH-5C cultures for 21 days. To simplify the experimental setup and reduce hepatocyte need, a substrate cocktail was applied for simultaneous uptake transporter (OATP1Bs, NTCP, OCT1, OAT2) activity measurements. Beside single donor lots, pooled hepatocyte lots were shown to be applicable for long-term culturing to mitigate interindividual variability. Our novel hepatic model provides a robust and reliable platform for drug screening and safety evaluation by extending in vitro functionality of hepatocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.